Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Shuji MurakamiRyota ShibakiYuji MatsumotoTatsuya YoshidaYasushi GotoShintaro KandaHidehito HorinouchiYutaka FujiwaraNoboru YamamotoYuichiro OhePublished in: Thoracic cancer (2020)
This study demonstrated that serum sPD-L1 level was an independent predictive and prognostic biomarker for NSCLC patients receiving anti-PD-1 antibody.